The Psychedelics Newsletter

Double-blind randomised clinical trials, Ketamine for treatment-resistant depression, US$900,000 grant for therapist training.

EXCLUSIVE: Angela Allbee, Oregon Psilocybin Services, Psilocybin therapy versus escitalopram, Is the psychedelic therapy bubble about to burst?

Standing on the shoulders of the Shulgins, Psilocybin therapy reduces heavy drinking days by 13%, Federally funded research to be made free to access.

The study of psilocybin in Thailand, 5.5 million in the US take psychedelic medicines, Does microdosing actually work?

COMPASS Pathways' new CEO Kabir Nath, A$250m VC fund created to support psychedelic healthcare, UK-based Awakn Life Sciences expands into US.

The kids are not alright, A need for 100,000 psychedelic-assisted therapists, NHS boosts children's mental health workforce by 40%

The power of bipartisan support, Canadian government sued over psilocybin access, The application of psychedelic medicines in psychiatry

Braving the bear market - investment in psychedelic healthcare, US administration expects psychedelic therapy in two years, NZ government grants MindBio NZ$1.4m

A public listing in psychedelic healthcare, Serotonin hypothesis of depression debased, The commercial potential of psychedelic medicine.

Access to psilocybin in Canada, The life of psychedelic researcher Ann Shulgin, Controlled study shows benefits of microdosing

Training psychedelic therapists, Filament Health announces C$2.5m private placement, MAPS starts study on MDMA-assisted group therapy.

Kernel Flow and the need for neuroimaging data, Veterans Affairs studies psychedelic medicines, Colorado activists file psilocybin ballot initiative.